Abstract
AbstractEtiology of sarcoidosis is still elusive, yet there has been considerable progress in various areas of basic and clinical research. In this review, we focus on ongoing or recently completed clinical–pharmacological studies in patients with sarcoidosis. Positive studies were published in well-characterized and homogenous subcohorts of sarcoid patients. Several drugs have shown a positive effect on sarcoidosis-associated fatigue, cutaneous sarcoidosis, and pulmonary hypertension in sarcoid patients. It seems that the recruitment of clinically precisely defined subcohorts is necessary to achieve positive outcomes in studies on sarcoidosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Seminars in respiratory and critical care medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
